The role of inflammation in DME

Article

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

Hideharu Funatsu, MD of the Tokyo Women's Medical University, Japan and colleagues conducted a retrospective case-control study of DME patients (n=53), patients with non-diabetic ocular disease (n=15) and diabetic patients who were free of retinopathy (n=8). The team examined samples of the vitreous fluid to determine levels of inflammatory factors, specifically vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and pigment epithelium-derived factor (PEDF).

The researchers found that DME patients demonstrated significantly higher levels of VEGF, ICAM-1, IL-6 and MCP-1 when compared with other patient groups, although the level of PEDF was significantly lower in the vitreous of DME patients when compared with other patient groups. In addition, the levels of each of these inflammatory factors in the vitreous were associated with the thickness of the retina at the central fovea. VEGF and ICAM-1 had a greater influence on the severity of DME than IL-6, MCP-1 or PEDF.

The team concluded that the level of these inflammatory factors - particularly VEGF and ICAM-1 - in the vitreous correlate significantly to the permeability of the retina and the severity of DME.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.